Spinoff Companies and Affiliates

Roswell Park Cancer Institute is helping to revitalize the region’s economy via the spinoff companies formed by Roswell Park Cancer Institute employees and utilizing technologies developed here. Committing the infrastructure, intellectual capital and necessary resources to convert its scientific discoveries into products/applications, RPCI has established a number of biotech spinoff companies, and formed strategic partnerships with investigators and centers throughout the world. Examples of biotech spinoff companies are:

Buffalo BioLabs, L.L.C. 

  • Located in Buffalo, NY
  • Founded by Andrei Gudkov, Ph.D., D.Sci., Buffalo BioLabs, L.L.C. (BBL) is an experienced preclinical Contract Research Organization (CRO) focused on expert management and performance of in vitro and in vivo studies capable of bringing new therapeutic agents to the stage of clinical testing.
  • BBL’s specialty is preclinical toxicity and efficacy testing in rodents using both conventional and custom models, with particular focus on evaluation of novel anticancer therapies.
  • BBL personnel have experience in all aspects of drug development from drug discovery and mechanistic analysis (e.g., development of readout systems, screening of chemical libraries, validation of hits, exploration of drug combinations) to pre-clinical animal studies (such as determination of MTD, in vivo proof of principle efficacy, optimal treatment regimens and effects in combination studies) and IND filing.

Canget BioTekpharma

  • Located in Buffalo, NY
  • Canget BioTekpharma was founded by Fengzhi Li, Ph.D.
  • Canget is a biotech and biopharma company, spun off from Roswell Park Cancer Institute and focuses on development of novel, cancer-targeting pharmaceutical compounds.
  • Canget aims to develop anticancer drugs that demonstrate exceptional efficacy against early- and late-stage cancers that have proven resistant to existing therapies by inhibiting a broad spectrum of antiapoptotic gene products and bypassing other drug-resistance mechanisms. In several preclinical studies, its lead agent, FL118, has been shown to be both safe and effective in eliminating tumors in animal models of several human cancer types.
  • Canget currently operates an active research laboratory in the UB CAT incubator at the New York State Center of Excellence in Bioinformatics & Life Sciences (CoE), 701 Ellicott Street, Buffalo, NY 14203, within the Buffalo Niagara Medical Campus (BNMC). Roswell Park will serve as a subcontractor for some of the SBIR funded research.
  • Canget recently won an SBIR grant from the National Cancer Institute to continue the development of FL-118.
  • Canget was showcased by the NCI at the 2014 National Council of Entrepreneurial Tech Transfer (NCET2) University Startups Conference.

Cleveland BioLabs, Inc.

  • Located in Buffalo, NY
  • Clinical-stage biotechnology company with a focus on oncology and orphan drug development located on the Buffalo Niagara Medical Campus
  • Formed in 2003 by Andrei V. Gudkov, Ph.D., D.Sci., Senior Vice President for Basic Science and Chairman of the Department of Cell Stress Biology
  • Pursuing the research, development and commercialization of proprietary products that have the potential to treat cancer, prevent and treat acute radiation syndrome and counteract the toxic effects of radio and chemotherapies for oncology patients
  • Publicly funded corporation (Nasdaq:CBLI) and has nine product candidates in their pipeline, most notably Entolimod (CBLB502), which is currently in clinical studies
  • These candidates are being developed directly by Cleveland BioLabs and their majority-owned subsidiaries, Incuron, L.L.C. and Panacela Labs, Inc.
  • For more information, visit www.cbiolabs.com.

Empire Genomics, L.L.C.

  • Located in Buffalo, NY
  • Privately funded molecular diagnostics company formed in 2006 that develops and offers a comprehensive menu of assay services for use in diagnosing and guiding precise therapeutic treatments for patients
  • Created by Norma Nowak, Ph.D., Director of the DNA Microarray and Genomics Facility at Roswell Park, to commercialize genomic technology developed at RPCI
  • Offers completely integrated services which are focused on providing diagnostic, prognostic, therapeutic and disease-monitoring information for the oncology market
  • For more information, visit www.empiregenomics.com.

Everon Biosciences

  • Headquartered in Buffalo, NY
  • Drug development company formed in 2011 by Andrei V. Gudkov, Ph.D., D.Sci., Senior Vice President for Basic Science and Chairman of the Department of Cell Stress Biology
  • Privately funded
  • Actively developing compounds that fight the aging process and age related diseases
  • For more information, visit www.tartiscorp.com.

Generate BioMed, Inc.

  • Headquartered in New York, NY
  • Formed in 2011 by Jeffrey Serbin, M.D., and Michael Rosenman
  • Privately funded Heat-Shock Vaccine discovery and development company formed to commercialize technology developed at Roswell Park Cancer Institute by John Subjeck, Ph.D., and Shawn Wang, Ph.D., both of Cell Stress Biology
  • Actively engaged in clinical studies and commercialization of licensed Heat-Shock protein technology (HSP 110) that may help the body form an immune response to antigens on cancer cells, essentially causing the antigens to function as a vaccine
  • Plans to operate as a Heat-Shock Vaccine discovery and development company researching and commercializing technologies linked to Heat-Shock proteins and their functions
  • For more information, contact admin@generatebiomed.com or visit www.generatebiomed.com.

Incuron, L.L.C.

  • Located in Buffalo, NY
  • Headquartered in Russia
  • Drug development company formed in 2009 by Andrei V. Gudkov, Ph.D., D.Sci., Senior Vice President for Basic Science and Chairman of the Department of Cell Stress Biology
  • Joint venture formed between Cleveland BioLabs and BioProcess Capital Ventures (a Russian investment company) and majority owned by Cleveland BioLabs
  • Actively developing compounds that fight cancer, specifically CBL0137 and CBL0102. CBL0137 is in clinical studies and CBL0102 has been granted orphan drug status.
  • For more information, visit www.incuron.com/en.

MimiVax, L.L.C.

  • Located in Buffalo, NY
  • Privately funded oncology vaccine development company formed in 2011 by Robert Fenstermaker, M.D., Chair of the Department of Neurosurgery, and Michael J. Ciesielski, Ph.D., Assistant Professor of Neurosurgery
  • Formed to develop and commercialize proprietary technology developed by Drs. Fenstermaker and Ciesielski and licensed from Roswell Park Cancer Institute involving oncology vaccines and targeted therapies for cancer treatment
  • The technology is intended to stimulate a strong immune response to the Survivin molecule, an important cellular protein involved in cancer cell metabolism, as a way of fighting cancer
  • Lead agent (MV-01) is in Phase 1 clinical studies
  • For more information, visit www.mimivax.com.

OmniSeq, L.L.C.

  • Located in Buffalo, NY
  • OmniSeq was designed as the physician’s solution to genomics based cancer testing, with a mission to set the standard for actionable results and rapid turnaround. OmniSeq offers cancer genomic testing and a network of collaborating physicians.
  • OmniSeq is raising the standard for genomic sequencing using a proprietary algorithm to resolve inconsistencies and yields unequivocal results with essentially no false positives — setting a new standard for actionable results and rapid turnaround.
  • The OmniSeqSM Precision Medical Technology platform consists of three components, including OmniSeq TargetSM, OmniSeq ConnectSM, and the OmniSeq Genomic NetworkSM.
  • For more information, visit http://www.omniseq.com/.

Oncotartis, Inc.

  • Headquartered in Buffalo, NY
  • Drug development company formed in 2011 by Andrei V. Gudkov, Ph.D., D.Sci., Senior Vice President for Basic Science and Chairman of the Department of Cell Stress Biology
  • Privately funded and has received funding from BioProcess (a Russian investment company)
  • Actively developing compounds that fight cancer
  • For more information, visit www.tartiscorp.com.

Panacela Labs, Inc.

  • Headquartered in Buffalo, NY
  • Drug development company formed in 2011 by Andrei V. Gudkov, Ph.D., D.Sci., Senior Vice President for Basic Science and Chairman of the Department of Cell Stress Biology
  • Joint venture founded by Cleveland BioLabs and Rusnano (a Russian investment company) in collaboration with Roswell Park Cancer Institute, Children’s Cancer Institute of Australia and Cleveland Clinic Foundation
  • Focused on developing five product candidates from the laboratory of Dr. Gudkov:
    • Revercom – Chemotherapy sensitizer
    • Mobilan – Adenovirus-based cancer immunotherapy
    • Arkil – Inhibitor of Androgen receptor targeting prostate cancer
    • Antimycon – Inhibitor of MYC oncogene
    • Xenomycins – Anti-bacterial and anti-fungal family of compounds
  • For more information, visit www.panacelalabs.com.

Photolitec, L.L.C.

  • Headquartered in Buffalo, NY
  • Photodynamic Therapy (PDT) and imaging technology company formed in 2010 by Ravindra Pandey, Ph.D., Distinguished Member of the Department of Cell Stress Biology
  • Privately funded and has received funding from Zhejiang Hisun Pharmaceutical Co. Ltd.
  • Actively engaged in the clinical development and commercialization of advanced proprietary technologies licensed from Roswell Park Cancer Institute and involving photosensitizing compounds used to identify cancer through medical imaging and for treating cancer by applying an appropriate light source to the photosensitized tumors
  • For more information, visit www.photolitec.org.

Simulated Surgical Systems, L.L.C.

  • Located in San Jose, CA
  • Formed in 2009 by Khurshid Guru, M.D., Director of Robotic Surgery at Roswell Park Cancer Institute and Thenkurussi Kesavadas, Ph.D., Director of the University at Buffalo’s Virtual Reality Lab
  • Privately funded
  • Manufactures and sells training simulators for the current DaVinci Robotic Surgery System
  • Formed to commercialize the ROSS™ robotic surgery simulator developed jointly by Drs. Guru and Kesavadas at Roswell Park Cancer Institute and the University at Buffalo
    • The ROSS™ robotic surgery simulator is a valuable training tool that provides surgeons hands-on training for robot-assisted surgery
  • For more information, visit www.simulatedsurgicals.com.